For the Inventor, By the Inventor

Enter inventor name

Cambridge, United Kingdom

Trevor Robert Perrior

USPTO Granted Patents = 12 (Patent Applications = 2)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 5)

Average Co-Inventor Count = 7.2

ph-index = 3

Forward Citations = 27(Granted Patents)

Location History:

Bury St Edmunds, GB (2012 - 2017)
Cambridge, GB (2013 - 2017)

Company Filing History:

The University of Edinburgh

Institute of Cancer Research: Royal Cancer Hospital (the)

The University of Manchester

Hemocorm Limited

Domainex Limited

St Georges Hospital Medical School

St George's Hosptial Medical School

where one patent can have more than one assignee

Years Active: 2012-2017

Loading Chart...

Loading Chart...

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9834549 - 3,3-disubstituted-(8-aza-bicyclo[3.2.1]OCT-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 (2017-12-05),

2. 9611223 - 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use (2017-04-04),

3. 9365564 - 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 (2016-06-14),

4. 9193689 - 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use (2015-11-24),

5. 8962609 - Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them (2015-02-24),

6. 8642621 - (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use (2014-02-04),

7. 8637453 - Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use (2014-01-28),

8. 8614209 - Amido-thiophene compounds and their use (2013-12-24),

9. 8541363 - Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use (2013-09-24),

10. 8389572 - Therapeutic delivery of carbon monoxide (2013-03-05),

11. 8362008 - Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors (2013-01-29),

12. 8299063 - Amido-thiophene compounds and their use (2012-10-30),

Title: The Innovative Mind of Trevor Robert Perrior

Introduction:

Trevor Robert Perrior, a brilliant inventor hailing from Cambridge, GB, has made significant contributions to the field of therapeutic compounds. With a total of 6 patents to his name, Perrior's work revolves around the development of novel pharmaceutical compositions to address various medical conditions.

Latest Patents:

Among his latest patents is the groundbreaking invention of 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use. These compounds exhibit the remarkable ability to inhibit PARP and/or Wnt signaling pathways, making them potential candidates for treating disorders ameliorated by the inhibition of these pathways, including various forms of cancer.

Career Highlights:

Perrior's illustrious career includes tenures at esteemed institutions such as the Institute of Cancer Research: Royal Cancer Hospital and The University of Manchester. Through his research and innovative approach, he has paved the way for advancements in the field of therapeutic compounds and pharmaceutical sciences.

Collaborations:

Throughout his journey, Perrior has collaborated with esteemed professionals in the field, including Rehan Aqil and Gary Karl Newton. Together, they have worked tirelessly to develop cutting-edge solutions that hold the potential to revolutionize the treatment of proliferative conditions and other medical disorders.

Conclusion:

In conclusion, Trevor Robert Perrior's relentless dedication to innovation and his remarkable ability to create novel therapeutic compounds highlight his invaluable contributions to the scientific community. His work stands as a testament to the power of ingenuity in shaping the future of healthcare and medicine.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…